Update on Anticoagulation Strategies in Patients with ECMO—A Narrative Review

Update on Anticoagulation Strategies in Patients with ECMO—A Narrative Review

The use of extracorporeal membrane oxygenation (ECMO) has recently increased exponentially. ECMO has become the preferred mode of organ support in refractory respiratory or circulatory failure. The fragile balance of haemostasis physiology is massively altered by the patient’s critical condition and...

Full description

Bibliographic Details
Main Authors:	Ján Šoltés, Michal Skribuckij, Hynek Říha, Michal Lipš, Pavel Michálek, Martin Balík, Michal Pořízka
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Journal of Clinical Medicine
Subjects:	ECMO anticoagulation heparin low-molecular-weight heparin COVID coagulation monitoring
Online Access:	https://www.mdpi.com/2077-0383/12/18/6067

Similar Items

Anticoagulation strategies in COVID-19 infected patients receiving ECMO support
by: Diaz Dayne, et al.
Published: (2023-09-01)

Is it time to switch to bivalirudin for ECMO anticoagulation?
by: Amir Navaei, et al.
Published: (2023-08-01)

Unusual drug response and hemodynamics, VA – ECMO. A case report
by: Fayaz Mohammed Khazi, et al.
Published: (2016-04-01)

Updates in Anticoagulation Therapy Monitoring
by: Hannah L. McRae, et al.
Published: (2021-03-01)

Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
by: Benjamin Seeliger, et al.
Published: (2021-01-01)

Anticoagulation Management in High Bleeding-Risk ECMO in Adults
by: Stefano De Paulis, et al.
Published: (2022-04-01)

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins
by: Aleksandra Jakimczuk, et al.
Published: (2022-04-01)

Anticoagulant Therapy in Moderate to Severe COVID-19 Patients
by: Agus Fitriyanto Achmad, et al.
Published: (2022-01-01)

INTRAOPERATIVE ANTICOAGULATION MONITORIZATION IN VASCULAR SURGERY – DOES A BLIND DOSIS FITS ALL?
by: Nuno Henriques Coelho, et al.
Published: (2019-05-01)

Anticoagulant Activity of Heparins from Different Animal Sources are Driven by a Synergistic Combination of Physical-chemical Factors
by: Stephan N.M.C.G. Oliveira, et al.
Published: (2022-10-01)

Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era
by: Kayla Torppey, et al.
Published: (2023-10-01)

COPD and Anticoagulation Therapy: Time for a New Approach?
by: Petris OR, et al.
Published: (2021-12-01)

Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model /
by: Walenga, J. M.

Studies on the anticoagulant, antimetastatic and heparin-binding properties of ghilanten-relared inhibitors /
by: Brankamp, R. G.

Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital setting
by: Harry Menon, et al.
Published: (2018-10-01)

Ewolucja leczenia przeciwzakrzepowego – od kleszcza i pijawki do tabletki
by: Wiesława Bednarek, et al.
Published: (2010-08-01)

Viscoelastometry for detecting oral anticoagulants
by: Philipp Groene, et al.
Published: (2021-03-01)

Safety of low-dose anticoagulation in extracorporeal membrane oxygenation using the Permanent Life Support System: a retrospective observational study
by: Kyungsub Song, et al.
Published: (2023-07-01)

Spontaneous Breast Haematoma after Heparin Anticoagulation
by: Imran Yaseen Gani, et al.
Published: (2020-06-01)

Neonatal ECMO
by: Cornelia Heleen Van Ommen, et al.
Published: (2018-10-01)

Not Just Anticoagulation—New and Old Applications of Heparin
by: Lixuan Zang, et al.
Published: (2022-10-01)

The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review
by: Aleksandra Frackiewicz, et al.
Published: (2023-05-01)

Heparin and its derivatives in the treatment of arterial thrombosis: a review
by: M. Dvorak, et al.
Published: (2010-11-01)

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects
by: Sumit Saxena, et al.
Published: (2022-08-01)

Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring
by: Sophie Susen, et al.
Published: (2020-06-01)

Anticoagulants: dose control methods and inhibitors
by: V. O. Bitsadze, et al.
Published: (2022-05-01)

Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass
by: Shvetank Agarwal, et al.
Published: (2012-01-01)

Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue
by: O. D. Ostroumova, et al.
Published: (2020-07-01)

A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19
by: Ying-feng Lu, et al.
Published: (2020-11-01)

Preparation, Anticoagulant and Antioxidant Properties of Glucosamine-Heparin Salt
by: Qin Miao, et al.
Published: (2022-10-01)

Applied Nanotechnologies in Anticoagulant Therapy: From Anticoagulants to Coagulation Test Performance of Drug Delivery Systems
by: Yuri B. G. Patriota, et al.
Published: (2021-05-01)

Effect of Anticoagulant Administration on the Mortality of Hospitalized Patients With COVID-19: An Updated Systematic Review and Meta-Analysis
by: Luojia Jiang, et al.
Published: (2021-08-01)

The use of anticoagulants in patients hospitalised with COVID-19
by: N Gloeck, et al.
Published: (2023-07-01)

Monocytes as Targets for Immunomodulation by Regional Citrate Anticoagulation
by: Giovana Seno Di Marco, et al.
Published: (2024-03-01)

Anticoagulant Treatment in Severe ARDS COVID-19 Patients
by: Adrian Ceccato, et al.
Published: (2022-05-01)

Osteoporosis and antithrombotic therapy
by: N. V. Brailova, et al.
Published: (2021-06-01)

Anticoagulation Management during Extracorporeal Membrane Oxygenation—A Mini-Review
by: Filip Burša, et al.
Published: (2022-12-01)

Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes
by: Al-Dorzi Hasan M., et al.
Published: (2022-11-01)

Pharmacological properties of hirudin and its derivatives : potential clinical advantages over heparin /
by: 422288 Monreal, Manuel, et al.

Bivalirudin for cardiac catheterization in a pediatric patient with religious objection to the use of porcine-derived heparin
by: A. Caskey, et al.
Published: (2021-08-01)